Document Detail


ERCC1 protein as a guide for individualized therapy of late-stage advanced non-small cell lung cancer.
MedLine Citation:
PMID:  22977580     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Excision repair cross-complementation group 1 (ERCC1) protein has been associated with cisplatin resistance. The objective of this study was to investigate the correlation between ERCC1 protein levels and the therapeutic effect of individualized therapy in advanced non-small cell lung cancer (NSCLC). A total of 190 advanced NSCLC patients were included in this study. Patients were randomized into either the individualized therapy group or the standard therapy group at a ratio of 2:1. Patients in the standard therapy group were treated with either gemcitabine plus cisplatin or vinorelbine plus cisplatin. The expression of ERCC1 protein in lung cancer tissues of patients from the individualized therapy group was detected with immunohistochemistry. Patients with low ERCC1 levels received either gemcitabine plus cisplatin or vinorelbine plus cisplatin, and patients with high levels received gemcitabine plus vinorelbine. The main outcome assessments were response rate (RR), overall survival (OS) and time to progression (TTP). Follow-up data were recorded until September 30, 2010. RR, 1-year survival rate and TTP were not statistically significant. The median survival time was 10.10 months in the standard therapy group (95% CI 8.48-11.92) and 13.59 months in the individualized therapy group (95% CI 11.86-14.74). The difference in median survival time was significantly different between these groups (P=0.036). The median survival time was longer in the individualized group compared to the standard therapy group. ERCC1 protein expression in advanced NSCLC patients, however, was not significantly correlated with RR, OS and TTP in the individualized therapy group. Therefore, this study suggests that ERCC1 protein levels should be assessed in combination with additional biomarkers to determine an optimal index for individualized therapy in advanced NSCLC patients.
Authors:
Zhiqiang Gao; Baohui Han; Jie Shen; Aiqin Gu; Dajiang Qi; Jinsu Huang; Chunlei Shi; Liwen Xiong; Yizhuo Zhao; Liyan Jiang; Huimin Wang; Yurong Chen
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-5-30
Journal Detail:
Title:  Experimental and therapeutic medicine     Volume:  2     ISSN:  1792-1015     ISO Abbreviation:  Exp Ther Med     Publication Date:  2011 9 
Date Detail:
Created Date:  2012-9-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101531947     Medline TA:  Exp Ther Med     Country:  -    
Other Details:
Languages:  ENG     Pagination:  811-815     Citation Subset:  -    
Affiliation:
Department of Pulmonary Medicine, Chest Hospital Affiliated with Shanghai Jiao Tong University, Shanghai 200030, P.R. China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dentigerous cysts associated with impacted supernumerary teeth in the anterior maxilla.
Next Document:  Non-Hodgkin's lymphoma of the testicle and bilateral adrenals detected by (18)F-FDG PET/CT.